ClinicalTrials.gg
CompletedNCT02170766Updated Jun 23, 2014

Bioavailability of BIBR 953 ZW in Healthy Subjects

A Phase 1 interventional study of BIBR 1048 low1 and BIBR 1048 low2 in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

To assess the extend of absorption of 12.5, 25, 50 and 100 mg of BIBR 1048 free base with and without coadministration of 40 mg pantoprazole.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects as determined by results of screening
  • Signed written in accordance with GCP and local legislation
  • Age ≥ 18 and ≤ 50 years
  • Broca ≥ - 20% and ≤ + 20%

Exclusion criteria

Exclusion Criteria:

  • Any findings of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  • History of current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  • History of orthostatic hypotension, fainting spells and blackouts
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  • Chronic or relevant acute infections
  • History of

    • allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
    • Any bleeding disorder including prolonged or habitual bleeding
    • Other hematologic disease
    • Cerebral bleeding (e.g. after a car accident)
    • Commotio cerebri
  • Intake of drugs with a long half-life (>24 hours) within 1 month prior to administration
  • Use of any drugs which might influence the results of the trial within 10 days prior to administration or during trial
  • Participation in another trial with an drug within 2 months prior to administration or during trial
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation within 1 month prior to administration or during the trial
  • Excessive physical activities within 5 days prior to administration or during the trial
  • Any laboratory value outside the clinically accepted reference range
  • History of any familial bleeding disorder
  • \< 150000/µl
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    BIBR 1048 low1

    Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole 1. BIBR 1048 12.5 mg without Pantoprazole 2. BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)

    Drug: BIBR 1048 low1 · Drug: Pantoprazole

  • Experimental
    BIBR 1048 low2

    Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole 1. BIBR 1048 25 mg without Pantoprazole 2. BIBR 1048 25 mg with 40 mg Pantoprazole (bid)

    Drug: BIBR 1048 low2 · Drug: Pantoprazole

  • Experimental
    BIBR 1048 medium

    Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole 1. BIBR 1048 50 mg without Pantoprazole 2. BIBR 1048 50 mg with 40 mg Pantoprazole (bid)

    Drug: BIBR 1048 medium · Drug: Pantoprazole

  • Experimental
    BIBR 1048 high

    Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole 1. BIBR 1048 100 mg without Pantoprazole 2. BIBR 1048 100 mg with 40 mg Pantoprazole (bid)

    Drug: BIBR 1048 high · Drug: Pantoprazole

06

What researchers measure

Primary outcomes

  1. AUC0-inf (Area under the concentration-time curve the time interval from 0 extrapolated to infinity) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  2. AUC0-tf (Area under the concentration-time curve over the time interval from 0 to the time of the last quantifiable concentration) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

Secondary outcomes

  1. Cmax (Maximum measured concentration) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  2. tmax (Time from dosing to the maximum concentration) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  3. MRTtot (Total mean residence time) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  4. CLtot/F (Total apparent clearance) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  5. Vz/F (Apparent volume of distribution) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  6. λz (terminal elimination rate constant) of BIBR 953 ZW

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  7. changes in activated partial thromboplastin time (aPTT)

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

  8. changes in international normalized ratio (INR)

    Time frame: Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2000 and a primary completion of Dec 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Oct 2000
Primary completionActual
Dec 2000
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02170766
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Oct 2000
Primary completion
Dec 2000
Last update
Jun 23, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion